The transcriptomic response of Acinetobacter baumannii to colistin and doripenem alone and in combination in an in vitro pharmacokinetics/pharmacodynamics model

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 5, 2014, Pages 1303-1313

  Henry, Rebekah ^a   Crane, Bethany ^a   Powell, David ^a   Lucas, Deanna Deveson ^a   Li, Zhifeng ^a,b   Aranda, Jesús ^a   Harrison, Paul ^a   Nation, Roger L ^a   Adler, Ben ^a   Harper, Marina ^a   Boyce, John D ^a   Li, Jian ^a  

^a MONASH UNIVERSITY   (Australia)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Carbapenems; Polymyxin resistance; Polymyxins

Indexed keywords

CHLORAMPHENICOL; COLISTIN; DORIPENEM; ETHIDIUM BROMIDE; RIBOSOME RNA; TETRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL OUTER MEMBRANE; BACTERIAL VIABILITY; BIOFILM; BIOINFORMATICS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG RESPONSE; FATTY ACID METABOLISM; GENE EXPRESSION; MAXIMUM PLASMA CONCENTRATION; MEMBRANE COMPONENT; MONOTHERAPY; NONHUMAN; PHARMACODYNAMICS; PHOSPHOLIPID TRANSFER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; TRANSCRIPTOMICS; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; SEQUENCE ANALYSIS; THEORETICAL MODEL; TIME FACTOR;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; GENE EXPRESSION PROFILING; MODELS, THEORETICAL; SEQUENCE ANALYSIS, RNA; TIME FACTORS;

EID: 84929742612     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku536     Document Type: Article

References (51)

1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538-82.
2. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
3. Lopez-Rojas R, Docobo-Perez F, Pachon-Ibanez ME et al. Efficacy of cecropin A-melittin peptides on a sepsis model of infection by panresistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 2011; 30: 1391-8.
4. Taccone FS, Rodriguez-Villalobos H, De Backer D et al. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 2006; 25: 257-60.
5. Telang NV, Satpute MG, Dhakephalkar PK et al. Fulminating septicemia due to persistent pan-resistant community-acquired metallo-blactamase (IMP-1)-positive Acinetobacter baumannii. Indian J Pathol Microbiol 2011; 54: 180-2.
6. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens:results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011; 66: 2070-4.
7. Park YK, Jung SI, Park KH et al. Independent emergence of colistinresistant Acinetobacter spp. isolates from Korea. Diagn Microbiol Infect Dis 2009; 64: 43-51.
8. Lee SY, Shin JH, Park KH et al. Identification, genotypic relation, and clinical features of colistin-resistant isolates of Acinetobacter genomic species 13BJ/14TU from bloodstreams of patients in a university hospital. J Clin Microbiol 2014; 52: 931-9.
9. Karaiskos I, Galani L, Baziaka F et al. Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis with intraventricular colistin after application of a loading dose: a case series. Int J Antimicrob Agents 2013; 41: 480-3.
10. Lesho E, Yoon EJ, McGann P et al. Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections. J Infect Dis 2013; 208: 1142-51.
11. Beceiro A, Llobet E, Aranda J et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother 2011; 55: 3370-9.
12. Moffatt JH, Harper M, Harrison P et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide. Antimicrob Agents Chemother 2010; 54: 4971-7.
13. Pelletier MR, Casella LG, Jones JW et al. Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2013; 57: 4831-40.
14. Clausell A, Garcia-Subirats M, Pujol M et al. Gram-negative outer and inner membrane models: insertion of cyclic cationic lipopeptides. J Phys Chem B 2007; 111: 551-63.
15. Wiese A, Gutsmann T, Seydel U. Towards antibacterial strategies: studies on the mechanisms of interaction between antibacterial peptides and model membranes. J Endotoxin Res 2003; 9: 67-84.
16. Sampson TR, Liu X, Schroeder MR et al. Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway. Antimicrob Agents Chemother 2012; 56: 5642-9.
17. Pournaras S, Poulou A, Dafopoulou K et al. Growth retardation, reduced invasiveness, and impaired colistin-mediated cell death associated with colistin resistance development in Acinetobacter baumannii. Antimicrob Agents Chemother 2014; 58: 828-32.
18. Heindorf M, Kadari M, Heider C et al. Impact of Acinetobacter baumannii superoxide dismutase on motility, virulence, oxidative stress resistance and susceptibility to antibiotics. PLoS One 2014; 9: e101033.
19. Deris ZZ, Akter J, Sivanesan S et al. A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADHquinone oxidoreductase activity. J Antibiot (Tokyo) 2014; 67: 147-51.
20. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-94.
21. Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/ pharmacodynamic model. Antimicrob Agents Chemother 2007; 51: 3413-5.
22. Hartzell JD, Neff R, Ake J et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48: 1724-8.
23. Bergen PJ, Tsuji BT, Bulitta JB et al. Synergistic killing of multidrugresistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2011; 55: 5685-95.
24. Deris ZZ, Yu HH, Davis K et al. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/ pharmacodynamic model. Antimicrob Agents Chemother 2012; 56: 5103-12.
25. Jernigan MG, Press EG, Nguyen MH et al. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2012; 56: 3395-8.
26. Pankuch GA, Seifert H, Appelbaum PC. Activity of doripenem with and without levofloxacin, amikacin, and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Diagn Microbiol Infect Dis 2010; 67: 191-7.
27. Principe L, Capone A, Mazzarelli A et al. In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection. Microb Drug Resist 2013; 19: 407-14.
28. Henry R, Vithanage N, Harrison P et al. Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids and poly-β-1,6-Nacetylglucosamine. Antimicrob Agents Chemother 2012; 56: 59-69.
29. Law CW, Chen Y, Shi W et al. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol 2014; 15: R29.
30. Iacono M, Villa L, Fortini D et al. Whole-genome pyrosequencing of an epidemic multidrug-resistant Acinetobacter baumannii strain belonging to the European clone II group. Antimicrob Agents Chemother 2008; 52: 2616-25.
31. Caspi R, Altman T, Billington R et al. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of Pathway/Genome Databases. Nucleic Acids Res 2014; 42: D459-71.
32. Bustin SA, Benes V, Garson JA et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55: 611-22.
33. Owen RJ, Li J, Nation RL et al. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007; 59: 473-7.
34. Kobayashi N, Nishino K, Yamaguchi A. Novel macrolide-specific ABC-type efflux transporter in Escherichia coli. J Bacteriol 2001; 183: 5639-44.
35. Lu S, Zgurskaya HI. MacA, a periplasmic membrane fusion protein of the macrolide transporter MacAB-TolC, binds lipopolysaccharide core specifically and with high affinity. J Bacteriol 2013; 195: 4865-72.
36. Okamoto K, Gotoh N, Nishino T. Extrusion of penem antibiotics by multicomponent efflux systems MexAB-OprM, MexCD-OprJ, and MexXY-OprM of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46: 2696-9.
37. Damier-Piolle L, Magnet S, Bremont S et al. AdeIJK, a resistancenodulation- cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrob Agents Chemother 2008; 52: 557-62.
38. Sugawara E, Nikaido H. Properties of AdeABC and AdeIJK efflux systems of Acinetobacter baumanii compared with those of AcrAB-TolC system of Escherichia coli. Antimicrob Agents Chemother 2014; 58: 7250-7.
39. Matsuyama S, Yokota N, Tokuda H. A novel outer membrane lipoprotein, LolB (HemM), involved in the LolA (p20)-dependent localization of lipoproteins to the outermembrane of Escherichia coli. EMBOJ 1997; 16: 6947-55.
40. Narita S, Tokuda H. An ABC transporter mediating the membrane detachment of bacterial lipoproteins depending on their sorting signals. FEBS Letters 2006; 580: 1164-70.
41. Bos MP, Robert V, Tommassen J. Biogenesis of the Gram-negative bacterial outer membrane. Annu Rev Microbiol 2007; 61: 191-214.
42. Malinverni JC, Silhavy TJ. An ABC transport system that maintains lipid asymmetry in the Gram-negative outer membrane. Proc Natl Acad Sci USA 2009; 106: 8009-14.
43. Choi AH, Slamti L, Avci FY et al. The pgaABCD locus of Acinetobacter baumannii encodes the production of poly-β-1,6-N-acetylglucosamine, which is critical for biofilm formation. J Bacteriol 2009; 191: 5953-63.
44. Amini S, Goodarzi H, Tavazoie S. Genetic dissection of an exogenously induced biofilm in laboratory and clinical isolates of E. coli. PLoS Pathog 2009; 5: e1000432.
45. Guerrero P, Collao B, Morales EH et al. Characterization of the BaeSR two-component system from Salmonella Typhimurium and its role in ciprofloxacin-induced mdtA expression. Arch Microbiol 2012; 194: 453-60.
46. Leblanc SK, Oates CW, Raivio TL. Characterization of the induction and cellular role of the BaeSR two-component envelope stress response of Escherichia coli. J Bacteriol 2011; 193: 3367-75.
47. Nishino K, Honda T, Yamaguchi A. Genome-wide analyses of Escherichia coli gene expression responsive to the BaeSR two-component regulatory system. J Bacteriol 2005; 187: 1763-72.
48. Keren I, Wu Y, Inocencio J et al. Killing by bactericidal antibiotics does not depend on reactive oxygen species. Science 2013; 339: 1213-6.
49. Kohanski MA, Dwyer DJ, Hayete B et al. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 2007; 130: 797-810.
50. Liu Y, Imlay JA. Cell death from antibiotics without the involvement of reactive oxygen species. Science 2013; 339: 1210-3.
51. Schneider D, Pohl T, Walter J et al. Assembly of the Escherichia coli NADH:ubiquinone oxidoreductase (complex I). Biochim Biophys Acta 2008; 1777: 735-9.